Pharmaceutical Research and Manufacturers of America and drug maker Johnson & Johnson each filed a friend of the court brief in June backing Novartis and United Therapeutics in those two companies’ appeals of a federal district judge’s November decision that while the 340B statute does not stop manufacturers from imposing any conditions on offers of 340B pricing, the statute does not permit all such conditions.
J&J in March imposed conditions on 340B pricing on 29 of its products when hospitals use contract pharmacies. HRSA has not sent it a 340B program violation letter yet but is expected to.
Pharmaceutical Research and Manufacturers of America and drug maker Johnson & Johnson each filed a friend of the court brief in June backing Novartis and United Therapeutics in those two companies’ appeals of a federal district judge’s November decision that while the 340B statute does not stop manufacturers from imposing any conditions on offers of 340B pricing, the statute does not permit all such conditions.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
